Next Article in Journal
Dominant Chemical Interactions Governing the Folding Mechanism of Oligopeptides
Previous Article in Journal
Revolutionizing Bone Regeneration with Grinder-Based Dentin Biomaterial: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 17
10.3390/ijms25179581
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy

by
Lizhen Zhao
†,
Hongbo Chen
†,
Fengli Lan
,
Jinjin Hao
,
Wenzhi Zhang
,
Ying Li
,
Yuhong Yin
,
Minchun Huang
and
Xiaoyan Wu
*
Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2024, 25(17), 9581; https://doi.org/10.3390/ijms25179581
Submission received: 11 August 2024 / Revised: 28 August 2024 / Accepted: 28 August 2024 / Published: 4 September 2024
(This article belongs to the Section Molecular Genetics and Genomics)
Browse Figures
Versions Notes

Abstract

:
Activating FLT3 mutations plays a crucial role in leukemogenesis, but identifying the optimal candidates for FLT3 inhibitor therapy remains controversial. This study aims to explore the impacts of FLT3 mutations in pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) and to compare the mutation profiles between the two types to inspire the targeted application of FLT3 inhibitors. We retrospectively analyzed 243 ALL and 62 AML cases, grouping them into FLT3-mutant and wild-type categories, respectively. We then assessed the associations between FLT3 mutations and the clinical manifestations, genetic characteristics, and prognosis in ALL and AML. Additionally, we compared the distinct features of FLT3 mutations between ALL and AML. In ALL patients, those with FLT3 mutations predominantly exhibited hyperdiploidy (48.6% vs. 14.9%, p < 0.001) and higher FLT3 expression (108.02 [85.11, 142.06] FPKM vs. 23.11 [9.16, 59.14] FPKM, p < 0.001), but lower expression of signaling pathway-related genes such as HRAS, PIK3R3, BAD, MAP2K2, MAPK3, and STAT5A compared to FLT3 wild-type patients. There was no significant difference in prognosis between the two groups. In contrast, AML patients with FLT3 mutations were primarily associated with leucocytosis (82.90 [47.05, 189.76] G/L vs. 20.36 [8.90, 55.39] G/L, p = 0.001), NUP98 rearrangements (30% vs. 4.8%, p = 0.018), elevated FLT3 expression (74.77 [54.31, 109.46] FPKM vs. 34.56 [20.98, 48.28] FPKM, p < 0.001), and upregulated signaling pathway genes including PIK3CB, AKT1, MTOR, BRAF, and MAPK1 relative to FLT3 wild-type, correlating with poor prognosis. Notably, internal tandem duplications were the predominant type of FLT3 mutation in AML (66.7%) with higher inserted base counts, whereas they were almost absent in ALL (6.3%, p < 0.001). In summary, our study demonstrated that the forms and impacts of FLT3 mutations in ALL differed significantly from those in AML. The gene expression profiles of FLT3-related pathways may provide a rationale for using FLT3 inhibitors in AML rather than ALL when FLT3 mutations are present.

1. Introduction

The Fms-like tyrosine kinase 3 (FLT3) gene, located on chromosome 13q12 [1], encodes a receptor crucial for the survival, proliferation, and differentiation of hematopoietic cells in both myeloid and lymphoid lineages [2]. The FLT3 receptor comprises four regions: an extracellular region, a transmembrane portion, a juxtamembrane domain (JMD), and an intracellular C-terminal region containing a tyrosine kinase domain (TKD), which includes TKD1 and TKD2 [2]. FLT3-activating mutations typically involve either internal tandem duplications (FLT3-ITD) in the JMD, leading to ligand-independent dimerization and activation, or point mutations in the TKD (FLT3-TKD) resulting in constitutive receptor activation. These mutations initiate a cascade of downstream signaling pathways, including PI3K/AKT, RAS/MAPK, and STAT5, promoting cellular proliferation and inhibiting apoptosis [2]. Over the past decade, advancements in DNA sequencing technologies, particularly next-generation sequencing (NGS), have significantly improved the survival rates for children with leukemia. A growing number of novel leukemogenic mutations have been identified, many of which exhibit sensitivity to FLT3 inhibitors at the cellular level [3,4,5]. However, the clinical significance of these non-canonical mutation sites in pediatric leukemia remains largely unexplored.
In acute myeloid leukemia (AML), the frequency of FLT3-ITD and TKD ranges from 9.7% to 16.5% and from 4.3% to 11.3%, respectively [6,7,8]. Notably, FLT3-ITD is linked to a deleterious prognosis, with a high FLT3-ITD allelic ratio indicating a particularly poor outcome in pediatric AML patients [9], and research on FLT3-TKD mutations shows inconsistent prognostic implications [6,10]. Meanwhile, in acute lymphoblastic leukemia (ALL), the mutation rate of FLT3 varies from 4.7% to 6.8% [3,11]. In certain subtypes of ALL, such as high hyperdiploidy and BCR-ABL1-like, there is an elevated frequency of FLT3 mutations [12,13]. Some research indicates a potential link to prognosis [14,15], while other studies on FLT3 mutations suggest that there may not be an impact on outcome in pediatric ALL [11,16,17]. Moreover, several studies [3,17] have demonstrated that the prognosis is influenced not only by FLT3 mutations per se but also significantly by the expression levels of FLT3, which are critically linked to patient outcomes [15,18,19]. Additionally, the oncogenesis of FLT3-ITD in AML is driven not merely by this specific mutation but also by a complex interplay of epigenetic modifications [20]. Consequently, why the identical FLT3 activating mutations lead to markedly divergent outcomes in ALL compared to AML remains an intriguing enigma.
Sorafenib is an oral, multi-targeted tyrosine kinase inhibitor. A study demonstrated that incorporating sorafenib into conventional chemotherapy significantly enhances overall survival (OS) in pediatric patients with FLT3-ITD-positive AML [21]. In contrast, evidence indicated that adding sorafenib to standard chemotherapy did not produce a response in patients with FLT3 mutations in ALL [5]. Furthermore, the data suggested that targeting FLT3 pathways was a viable therapeutic strategy in T-cell ALL with PRC2 mutations [22]. Consequently, despite these advancements, the mechanisms by which FLT3 mutations drive leukemogenesis and the identification of patients who could potentially benefit from FLT3 inhibitors remain insufficiently elucidated.
Considering the role of FLT3 in the pathogenesis of ALL and AML and the fact that identifying the beneficiaries of FLT3 inhibitors remains an enigma, we conducted a comprehensive analysis of pediatric ALL and AML cases. Specifically, we examined disease characteristics at initial diagnosis, co-mutations, related gene expression patterns, and clinical outcomes.

2. Results

2.1. Association of FLT3 Gene Mutations with Clinical Characteristics and Remission Status

This study included a total of 305 patients with documented genetic data: 243 with ALL and 62 with AML. Among these, 35 ALL patients (14.4%) and 20 AML patients (32.3%) harbored FLT3 mutations.
Among the cohort of 243 ALL patients, 215 cases (88.5%) had B-cell ALL (B-ALL), of which 35 were found to have FLT3 mutations. Interestingly, there was a notable increase in hyperdiploidy cases (48.6% vs. 14.9%, p < 0.001) and a decrease in ETV6-RUNX1 fusion transcript cases (0.0% vs. 18.8%, p = 0.005) in the FLT3 mutation group. Additionally, the proportion of patients achieving minimal residual disease (MRD)-negative status on day 19 was significantly lower in the FLT3 mutation subgroup compared to the FLT3 wild-type subgroup (21.2% vs. 45.3%, p = 0.009). A detailed comparison between the mutation and non-mutation subgroups is presented in Tables S1 and S2.
Among the AML patients included in the study, the presence of an FLT3 mutation was associated with a significantly elevated white blood cell count at diagnosis (82.90 G/L vs. 20.36 G/L, p = 0.001). Furthermore, the FLT3 mutation group exhibited a higher prevalence of the NUP98 fusion transcript (30.0% vs. 4.8%, p = 0.018) and a lower frequency of the AML1-ETO fusion transcript (10.0% vs. 42.9%, p = 0.010). Notably, there were no significant differences observed in the treatment response. Additional details regarding these findings can be found in Tables S3 and S4.

2.2. The Characteristics of FLT3 Mutations

We identified a total of 48 FLT3 mutations in 35 ALL patients, encompassing various mutation types. Among the 20 AML patients, 27 FLT3 mutations were found (Figure 1A,B). Notably, the spectrum of mutations differed between ALL and AML. In ALL patients, ITD and canonical TKD mutations constituted only 6.3% and 18.8% of FLT3 mutation events, respectively. Conversely, these mutations were predominant in AML patients, accounting for 66.7% (p < 0.001) and 14.8% of events, respectively (Figure 1C–E).
Additionally, NGS revealed numerous novel non-canonical FLT3 mutations, which could be classified into three subtypes: non-canonical point mutations (NCPM), insertion/deletion variants causing in-frame amino acid alterations, and other insertions (INS). The prevalence of NCPMs was significantly higher in ALL patients (58.3%) compared to AML patients (11.1%, p < 0.001), whereas the incidence of other types of mutations was 16.6% vs. 7.4% (Figure 1C–E).
The median length of insertions in AML was 46.5 base pairs (bp) (range: 18–102 bp), significantly greater than the median length in the ALL group, which was 6 bp (range: 3–12 bp, p = 0.002). (Figure 1F).

2.3. Patterns of Co-Occurrence in FLT3 Gene Mutations

In our investigation of 35 ALL patients with FLT3 gene mutations, we observed that co-mutations associated with diseases primarily affected signaling pathways and transcription factors, accounting for 51.0% and 30.2% of cases, respectively (Figure 2A,C). Specifically, mutations in signaling pathways were identified in NRAS (7 patients), KRAS (10 patients), and PTPN11 (7 patients). Transcription factor mutations involved CREBBP, XBP1, CTCF, MYC, MGA, and ETV6. Additionally, mutations in histone methylation and tumor suppressor genes were found in 7.5% and 3.8% of cases, respectively, with sporadic mutations in EP300, ATG2B, SMARCA4, and ARID5B.
Similarly, our findings indicated that signaling pathways and transcription factors each accounted for 32.0% and 28.0% of AML cases with co-mutations, respectively. The principal signaling pathway mutations include NRAS, PTPN11, and KIT, while the transcription factors involved were RUNX1, IKZF1, ZBTB7A, CEBPA, and MYC. These FLT3 mutations are also accompanied by histone methylation alterations, observed in 4.0% of cases. A distinctive feature of AML was the prevalent occurrence of chromatin modifiers (12.0%), particularly in genes like ASXL2 and KDM6A. Furthermore, occasional mutations were identified in genes such as IDH1, RBBP4, and RAD21 (Figure 2B,D).

2.4. FLT3 and Their Related Gene Expressions

Overexpression of FLT3 may lead to its activation as a receptor and serve as a prognostic marker in pediatric acute leukemia. We analyzed FLT3 levels and related pathway genes in 206 ALL and 57 AML patients using RNA sequencing data. The expression levels of genes involved in the FLT3 signaling pathway (Figure 3), including FLT3, KRAS, HRAS, NRAS, PIK3CA, PIK3CB, PIK3CD, PIK3R3, AKT1, AKT2, AKT3, MTOR, CHUK, IKBKB, IKBKG, BAD, BRAF, RAF1, MAP2K1, MAP2K2, MAPK1, MAPK3, STAT3, STAT5A, and STAT5B were compared. Gene expression levels were measured using fragments per kilobase of exon model per million mapped fragments (FPKM).
In the ALL cohort, the median expression of FLT3 in the mutant group was 108.02 [85.11, 142.06] FPKM, significantly higher than in the non-mutant group (p < 0.001), which had a median expression of 23.11 [9.16, 59.14] FPKM. Concurrently, the expression levels of HRAS (2.35 [1.57, 3.16] FPKM vs. 2.77 [2.08, 3.88] FPKM, p = 0.044), PIK3R3 (1.33 [0.69, 1.77] vs. 2.02 [1.03, 3.84] FPKM, p = 0.002), BAD (3.39 [2.25, 4.52] FPKM vs. 4.28 [3.11, 5.34] FPKM, p = 0.018), MAP2K2 (6.84 [4.03, 9.53] FPKM vs. 8.06 [6.88, 10.10] FPKM, p = 0.017), MAPK3 (5.21 [3.92, 6.62] FPKM vs. 6.01 [5.01, 7.16] FPKM, p = 0.028), and STAT5A (12.31 [9.28, 15.57] FPKM vs. 14.58 [11.02, 19.61] FPKM, p = 0.029) were significantly lower in the mutant group compared to the non-mutant group. No notable differences were observed in the expression levels of the remaining genes between the two groups (Table 1).
Interestingly, significant increases in expression levels were observed in the FLT3 mutant group compared to the wild-type group for several genes in the AML cohort: FLT3 (74.77 [54.31, 109.46] vs. 34.56 [20.98, 48.28] FPKM, p < 0.001), PIK3CB (23.05 [18.81, 25.80] FPKM vs. 17.60 [13.28, 19.85] FPKM, p = 0.006), AKT1 (9.66 [8.38, 11.61] FPKM vs. 7.40 [5.55, 8.88] FPKM, p = 0.003), MTOR (9.33 [7.75, 11.35] FPKM vs. 7.70 [6.79, 8.65] FPKM, p = 0.006), BRAF (13.38 [11.63, 15.12] FPKM vs. 11.37 [9.61, 13.19] FPKM, p = 0.015) and MAPK1 (14.84 [13.07, 17.90] FPKM vs. 12.72 [11.02, 14.92] FPKM, p = 0.029), while the expression levels of the other genes did not show significant differences between the two groups (Table 2).

2.5. Prognostic Impacts of FLT3 Mutations

With a median follow-up time of 29 ± 1.5 months for OS, among the total 20 patients who died in the ALL cohort, one was found to harbor an FLT3 mutation. Due to the small number of deaths, the median survival time was not reached. There were no statistically significant differences in OS (96.6% vs. 87.8%, p = 0.23) and event-free survival (EFS) (93.6% vs. 69.1%, p = 0.12) between the mutation and wild-type groups (Figure S1A,B).
Among children with AML, 4 out of the 13 patients who died had an FLT3 mutation. The presence of the FLT3 mutation was not associated with significantly inferior outcomes compared to the non-mutation subgroup (OS: 71.5% vs. 70.7%, p = 0.86; EFS: 48.6% vs. 52.9%, p = 0.98), with a median follow-up time of 28.0 ± 5.9 months for OS (Figure S1C,D).

3. Discussion

FLT3-activating mutations interfere with the differentiation and maturation processes of hematopoietic cells [2]. Recent studies have increasingly demonstrated that FLT3 inhibitors exert a beneficial effect in a subset of patients; however, the specific nature of FLT3 mutations that may benefit pediatric ALL and AML patients remains to be determined [3,4,15,23,24]. This study involved a comprehensive clinical, genomic, and transcriptomic evaluation of FLT3 to elucidate its variations and their pathological impacts in pediatric ALL and AML, thereby informing the use of FLT3 inhibitors. Our findings indicated that, in patients with FLT3 mutations, point mutations predominated in ALL, whereas ITD mutations were more common in AML. Further transcriptomic analysis revealed high FLT3 expression in both conditions but with distinct differences in the expression levels of FLT3-related pathway genes. These distinctions suggest that FLT3 activation led to divergent downstream signaling cascades, which may serve as a critical determinant in the choice of FLT3 inhibitor therapy.
This investigation provided an extensive overview of the clinical characteristics of ALL and AML harboring FLT3 mutations utilizing NGS. The FLT3 mutation rates were found to be 14.4% for ALL and 32.3% for AML, indicating an increase compared to previous studies [5,6], demonstrating the superior sensitivity and enhanced detection capabilities of NGS [25,26]. In the context of ALL, no marked leukocytosis was detected, in concordance with previously published reports [3,16]. A significantly increased tendency for FLT3 mutations was observed with high hyperdiploidy, consistent with other studies [3,13,16]. However, the significantly increased frequency of FLT3 mutations in B-ALL observed in this study remains inconclusive [3,5]. Further investigation with larger sample sizes is warranted to clarify the proportions of FLT3 mutations in B-ALL and T-cell ALL. Strikingly, in our cohort, there was a pronounced inverse correlation between FLT3 mutations and ETV6-RUNX1, suggesting a mutually exclusive relationship between FLT3 mutation and ETV6-RUNX1 in ALL tumorigenesis, which may be attributed to the propensity of mutated patients to lack the fusion gene [27]. In AML, the FLT3 mutation was significantly associated with NUP98 [28] fusions and indicated a higher tumor burden [4]. Preclinical trials have also shown that mice harboring both FLT3-ITD and NUP98 fusion genes exhibited more aggressive leukemia with a shorter latency period [29]. Additionally, a subtle negative association was noted between FLT3 mutations and the presence of the AML1-ETO translocation, typically representing a low-risk feature [30], indicating diverse contributions to leukemogenesis.
The above analysis detailed the diverse mutational forms of FLT3 in ALL and AML, along with the expression spectra of FLT3-related pathway genes, suggesting differential activation of FLT3-related downstream signaling pathways. This assertion can be elaborated from three distinct perspectives. Firstly, among 35 pediatric ALL patients with FLT3 mutations, various forms such as TKD, ITD, INS, and deletion/insertion were identified, with NCPM being predominant, echoing earlier results [3,6]. In contrast, among 20 AML patients with FLT3 mutations, 18 exhibited the FLT3-ITD subtype, characterized by inserted bases ranging from 18 to 102. These observations emphasized the distinct roles that FLT3 mutations may play in the pathogenesis of ALL and AML. ITD mutations in the JMD disrupted its autoinhibition by elongating the domain, rather than by an increased number of tyrosine residues, showing distinct structural changes resulting from different amino acid alterations [31]. Concurrently, research has demonstrated that FLT3 point mutations can modify the substrate specificity of protein kinases [32]. Consequently, we inferred that the distinct mutation patterns in ALL and AML may affect various docking sites and act upon different substrates. Secondly, FLT3-ITD mutants induce receptor autophosphorylation and promote interleukin-3-independent growth in Ba/F3 cells, strongly activating STAT5 and MAPK pathways. In contrast, ligand-stimulated FLT3 wild-type activates AKT and MAPK pathways without affecting STAT5 [33]. Point mutations in the JMD of FLT3 in AML exhibited a diminished transforming capability, which was associated with reduced autophosphorylation of the receptor and its downstream target STAT5 [34]. Chatain et al. elucidated that FLT3 JMD point mutations and deletions in AML led to phosphorylation of both STAT3 and STAT5, while FLT3-ITD mainly activated STAT5 over STAT3 [35]. The Y842 mutation in the FLT3-ITD background impairs the RAS/ERK pathway and delays tumor formation [36]. Furthermore, substitutions of tyrosine residues 589 and 591 with phenylalanine in FLT3-ITD can disrupt STAT5 signaling without affecting tyrosine kinase activity, thus preventing the myeloproliferative phenotype in murine bone marrow cells [37]. Collectively, these findings suggest that the precise degree and specific pathways of downstream signaling activation play a crucial role in leukemia development beyond just receptor activation. Thirdly, FLT3-related signaling pathways primarily include the JAK-STAT, MAPK, and PI3K-AKT pathways [2]. We conducted an analysis of the expression levels of related genes. Transcriptome data analysis revealed differential expression profiles of FLT3-associated pathway genes in ALL and AML. In ALL, genes in the relevant signaling pathways were downregulated in the mutation group, whereas in AML, they were upregulated, highlighting the differing roles of FLT3 mutations in the development of these leukemias. This may partially explain why FLT3-ITD patients have a poor prognosis and provide robust evidence for the advancement of targeted and precise therapeutic strategies.
The research further revealed that, regardless of whether the cases involved pediatric ALL or AML, FLT3 mutations did not correspond with a worse prognosis. The underlying reasons in ALL are analyzed as follows. In ALL patients, firstly, it is apparent that patients with FLT3 mutations frequently present with hyperdiploidy, which is indicative of chemosensitivity and a favorable prognosis [38,39,40]. Secondly, the mutations are primarily point mutations, which generally exerted a less significant influence on downstream signaling pathways due to lower autophosphorylation [34], with only three individuals found to carry the ITD mutation. In AML cases, the prevalence of FLT3-ITD mutations markedly increased, reaching up to 90% among patients receiving treatment. The cytological remission rate was 75%, which is similar to the 79.8% total post-induction cytological complete remission rate reported for the Chinese Children’s Leukemia Group (CCLG)-AML-2015 regimen in the Homoharringtonine-based induction group and 75% in the high-risk group [41]. Regarding prognostic outcomes, in the cohort of 18 AML patients harboring FLT3-ITD mutations, three individuals withdrew from treatment and were subsequently excluded from the prognostic evaluation. Details of the treatment regimen are illustrated in Table S5. Specifically, three patients terminated their therapy during the induction chemotherapy phase. Of the seven patients who underwent hematopoietic stem cell transplantation (HSCT), it was the incorporation of FLT3 inhibitors that enabled three of them to achieve complete remission and qualify for HSCT. Ultimately, five patients enjoyed favorable prognoses [9,42], although two died due to transplant-related complications. Conversely, three patients received intensified chemotherapy without FLT3 inhibitors. This resulted in two deaths due to severe post-chemotherapy infections, and one patient remained in non-remission, thereby missing the opportunity for HSCT, leading to a poor outcome. An additional patient, who received intensive chemotherapy augmented with FLT3 inhibitors, remained in sustained remission. This aligns closely with recent studies indicating the significant potential of FLT3 inhibitors for AML patients with FLT3-ITD mutations [21,23]. Encouragingly, a report indicated that, following HSCT relapse and the detection of a FLT3-TKD mutation, an early T-cell precursor ALL patient achieved a second complete remission and MRD negativity with gilteritinib treatment [43]. Moreover, venetoclax works synergistically with gilteritinib in FLT3 wild-type high-risk AML by suppressing MCL-1 [44]. These observations imply that FLT3 inhibitors may have potential applications in non-FLT3-ITD cases. Based on the differential downstream gene expression profiles in our transcriptomic data for ALL and AML, we infer that these benefits from FLT3 inhibitors may be attributed to more comprehensive mechanisms involving the activation of downstream signaling pathways.
The present study investigated the patterns of concurrent FLT3 mutations in ALL and AML to identify specific gene–gene interactions that play a key role in the emergence and progression of these diseases. Research into AML has demonstrated that FLT3 wild-type high-risk patients with mutations in NPM1, DNMT3A, co-occurring NPM1/DNMT3A, “activated signaling,” and “DNA methylation” genes showed improved OS with sorafenib maintenance [45]. Additionally, midostaurin has been shown to potentially improve OS and disease-free survival in FLT3-ITD AML patients with chromatin-spliceosome mutations [46], and relapsed/refractory FLT3-mutated AML patients with DNMT3A/NPM1 co-mutations experienced the most positive outcomes when treated with gilteritinib [47]. These findings imply that genetic patterns are crucial in the pathogenesis and treatment of AML. In our study, the distribution of the top three co-mutated genes in ALL, which were related to signaling pathways, transcription factors, and histone methylation, was similar to the mutational spectrum observed in 219 pediatric ALL [27]. This pattern seemingly suggested that FLT3 mutations did not have unique co-mutated partner genes. In AML, we found that concomitant mutations exhibited a wide variety of irregular patterns. Due to the limited sample size, it is currently not feasible to investigate the prognostic relevance of FLT3 mutations accompanied by other genetic mutations through subgroup analysis. It is important to interpret these findings with caution due to the finite sample size. Further data collection is necessary to validate these incidences and to explore the relationships between these genetic factors and prognosis.
Our study has some limitations. Due to its retrospective nature, we did not investigate downstream signaling molecule phosphorylation levels, which are crucial for elucidating the underlying pathogenic mechanisms. Moreover, the single-center design of the study led to limited sample sizes, preventing robust analysis of some genetic pattern subgroups and their relationship with prognosis. Future studies should leverage multi-center data to focus on co-mutations and related signaling pathways. Ultimately, assessing drugs that target these pathways and conducting translational research are expected to enhance treatment outcomes for patients with FLT3 mutations and other genetic alterations.

4. Methods and Materials

4.1. Participants and Study Design

A total of 274 de novo ALL and 74 newly diagnosed AML patients were identified at our hospital between January 2019 and January 2023. After excluding those who did not complete comprehensive genetic testing for hematologic tumors, 243 ALL and 62 AML patients were included in the study. Refer to Figure S2 for a detailed description of the study process. All patients were diagnosed with ALL or AML based on morphology, flow cytometry, immunohistochemistry, and genetic testing, and received either the Chinese Children’s Cancer Group (CCCG)-ALL-2015/2020 protocol or the CCLG-AML-2015/2019 regimen. Detailed treatment protocols are provided in Tables S6 and S7. This study was approved by the Ethics Committee of the Union Hospital of Tongji Medical College, Huazhong University of Science and Technology (No. 2024–0034).

4.2. Chemotherapy Protocol

The therapeutic approach for ALL patients was aligned with similar protocols, specifically CCCG-ALL-2015 or CCCG-ALL-2020, with early-stage patients adhering to the 2015 plan. The specific treatment protocols are detailed in Supplemental Tables S6 and S7. Similarly, for AML, chemotherapy regimens are provided in Tables S8 and S9. Information about HSCT treatment for the patients can be found in Table S10.

4.3. Comprehensive Genetic Testing for Hematologic Tumors

Genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (TIANGEN Biotech (Beijing) Company Limited, Beijing, China) according to the manufacturer’s instructions. The DNA sample was quantified by Qubit dsDNA BR Assay kit (Nanjing Vazyme Biotech Company Limited, Nanjing, China), and DNA integrity was assessed by agarose gel electrophoresis (Shanghai GeneRay Biotech Company Limited, Shanghai, China). DNA was sheared on the Covaris M220 focused ultrasonicator (Gene Technology (Shanghai) Company Limited, Shanghai, China). All libraries were prepared using the KAPA HTP Library Preparation Kit (Shanghai GeneRay Biotech Company Limited, Shanghai, China) according to the manufacture’s instruction. Fragmented DNA was repaired, 3’dA-tailed, ligated with Illumina adapters, size selected, amplified, and assessed using the Agilent 2100 Bioanalyzer (Agilent Bio (Hangzhou) Company Limited, Hangzhou, Zhejiang Province, China). For a targeted capture library of structural variant and single nucleotide variant analysis, a customized panel of biotinylated oligoprobes (Shanghai GeneRay Biotech Company Limited, Shanghai, China) was designed to capture the likely break regions of genes and hotspot mutational regions of hematological malignancies that were identified in earlier leukemia sequencing studies. The captured DNA library was finally amplified and sequenced on Illumina Novaseq 6000 sequencer (Illumina (China) Scientific Equipment Company Limited. Shanghai, China) for paired reads at 150 bp. The raw data were converted from BCL files to FASTQ format using Illumina CASAVA 1.8 (Illumina (China) Scientific Equipment Company Limited. Shanghai, China). The reads were aligned to the GRCh37/hg19 human genome reference using BWA (Broad Institute of MIT and Harvard, Cambridge, MA, USA), and further processed with samtools, picard, and GATK (Broad Institute, Cambridge, MA, USA) to eliminate duplicate sequences and detect genetic variants. All discovered variants were assessed by consulting databases such as NCBIdbSNP (https://www.ncbi.nlm.nih.gov/snp/ Access Date: January 2019 to January 2023), OMIM (https://www.ncbi.nlm.nih.gov/omim/ Access Date: January 2019 to January 2023), HGMD (http://www.hgmd.org Access Date: January 2019 to January 2023), and NCBI ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/ Access Date: January 2019 to January 2023).

4.4. RNA Sequencing

RNA Extraction and Quality Assessment: Bone marrow or blood samples were collected using the PAXgene Blood RNA Tube (Chongqing Yes Service Biomedical Tech, Inc. Chongqing, China). Total RNA was extracted using the MagMAX (Invitrogen Trading (Shanghai) Company Limited. Shanghai, China) for Stabilized Blood Tubes RNA Isolation Kit (Invitrogen Trading (Shanghai) Company Limited. Shanghai, China) (or PAXgene Blood RNA Tubes) (Invitrogen Trading (Shanghai) Company Limited. Shanghai, China). Purification was carried out with the NanodropOne (Thermofisher, Invitrogen Trading (Shanghai) Company Limited. Shanghai, China). RNA integrity was assessed using the Qseq400 system (BIOPTIC, Bioptic Inc Technology Company Limited. New Taipei City, Taiwan, China) with the R1 cartridge, and samples with an RQN of ≥5 were deemed suitable for subsequent library preparation.
Library Preparation and Sequencing: Libraries were prepared using the KAPA RNA HyperPrep Kit (Kapabiosystems, cat.KK8540, Shanghai EAST STAR Science & Technology Import & Export Company Limited, Shanghai, China). rRNA was removed using the KAPA RiboErase (HMR) Kit (Kapabiosystems, cat.KK8482, Shanghai EAST STAR Science & Technology Import & Export Company Limited, Shanghai, China). Library construction was performed with 1 µg of total RNA per sample, following the kit manual’s instructions. Post-construction, library concentration was measured with the Qubit 3.0 Fluorometer (Shanghai Jiahe Biological Technology Company Limited, Shanghai, China.) using the Qubit dsDNA HS Assay Kit (Thermofisher, Invitrogen Trading (Shanghai) Company Limited. Shanghai, China), and library size was assessed using the Qseq400 system (Bioptic Technology Company Limited. New Taipei City, Taiwan, China) with the S2 cartridge. Finally, the libraries were sequenced on the Illumina NovaSeq X Plus platform (Illumina (China) Scientific Instruments Company Limited. Shanghai, China), producing paired-end reads of 150 bp, resulting in over 15 GB of raw data.

4.5. Treatment Response

Morphological and immunological evaluation of bone marrow smears was performed on Day 19 and Day 46 for ALL patients, and a bone marrow assessment was conducted on Day 28 of each chemotherapy phase for AML patients. Patients were classified based on their blast cell counts into three categories: M1 (blast cells < 5%), M2 (≥5%, <25%), and M3 (≥25%). Complete remission was defined as bone marrow containing less than 5% blasts accompanied by the regeneration of normal hematopoietic cells and MRD less than 10−4.

4.6. Follow-Up

All cases were followed up through outpatient visits or telephone consultations, with follow-ups concluding in December 2023. Treatment outcomes were assessed using OS and EFS metrics. OS was defined as the duration from the date of diagnosis to either death or the last follow-up for surviving patients. Relapse, death and loss to follow-up in three situations—due to the progression of the primary disease, definitive abandonment of treatment, or unstable vital signs at the time of departure—were defined as events. However, those lost to follow-up after completing most of their chemotherapy and achieving remission were not defined as events. EFS was defined as the interval from the start of treatment to the occurrence of any event, or to the last follow-up, whichever occurred first.

4.7. Statistical Analysis

The baseline characteristics of the patients were presented as frequencies and percentages for categorical data and as medians with interquartile ranges for continuous variables. Categorical variables were analyzed using chi-squared tests or continuity-corrected chi-squared tests, as appropriate. Non-parametric tests were used for continuous variables. OS and EFS were calculated using the Kaplan–Meier method, and comparisons between cohorts were made using the log-rank test. All p-values were calculated using two-tailed tests. A p-value of less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS (IBM, version 24.0), Prism (version 9), and R (version 4.3.3).

5. Conclusions

In conclusion, our study demonstrated that the FLT3 mutation in ALL did not affect prognosis, unlike in AML, where prognosis could be improved through HSCT and FLT3 inhibitor therapy. FLT3 inhibitors might be more therapeutically beneficial for AML compared to ALL when FLT3 mutations are present, as indicated by the expression profiles of FLT3-related pathways.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms25179581/s1.

Author Contributions

Conceptualization, L.Z., H.C. and X.W.; data curation, L.Z., H.C., F.L., J.H., W.Z., Y.L., Y.Y. and M.H.; formal analysis, L.Z., H.C. and X.W.; funding acquisition, H.C. and X.W.; investigation, L.Z. and X.W.; methodology, L.Z. and X.W.; project administration, X.W.; resources, L.Z., H.C. and X.W.; software, L.Z.; supervision, H.C., F.L., J.H., W.Z., Y.L., Y.Y., M.H. and X.W.; validation, L.Z. and X.W.; visualization, L.Z. and X.W.; writing–original draft, L.Z.; writing–review and editing, H.C., F.L., J.H., W.Z., Y.L., Y.Y., M.H. and X.W. All authors have read and agreed to the published version of the manuscript.

Funding

This project received funding through the Innovative Research Grant from the Science and Technology Department of Hubei Province (grant number 2023BCB026) and the Key Program of The Independent Design Project of the National Clinical Research Center for Child Health (grant number I23J0005).

Institutional Review Board Statement

The research was conducted in compliance with the Declaration of Helsinki and received approval from the ethics committee of Union Hospital at Tongji Medical College, Huazhong University of Science and Technology (No. 2024-0034).

Informed Consent Statement

Due to the study’s retrospective design, informed consent was waived.

Data Availability Statement

Requests for research data can be made through correspondence upon reasonable request.

Acknowledgments

We extend our heartfelt thanks to all the doctors from the Department of Pediatrics at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, along with all the patients and their families who took part in this study.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

  1. Rosnet, O.; Matteï, M.-G.; Marchetto, S.; Birnbaum, D. Isolation and Chromosomal Localization of a Novel FMS-like Tyrosine Kinase Gene. Genomics 1991, 9, 380–385. [Google Scholar] [CrossRef] [PubMed]
  2. Grafone, T.; Palmisano, M.; Nicci, C.; Storti, S. An Overview on the Role of FLT3-Tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Treatment. Oncol. Rev. 2012, 6, 8. [Google Scholar] [CrossRef]
  3. Gutierrez-Camino, A.; Richer, C.; Ouimet, M.; Fuchs, C.; Langlois, S.; Khater, F.; Caron, M.; Beaulieu, P.; St-Onge, P.; Bataille, A.R.; et al. Characterisation of FLT3 Alterations in Childhood Acute Lymphoblastic Leukaemia. Br. J. Cancer 2023, 130, 317–326. [Google Scholar] [CrossRef] [PubMed]
  4. Ge, S.; Qiu, Q.; Dai, H.; Shen, X.; Wu, T.; Du, J.; Wan, C.; Shen, H.; Wu, D.; Xue, S.; et al. Mutation Spectrum of FLT3 and Significance of Non-canonical FLT3 Mutations in Haematological Malignancy. Br. J. Haematol. 2023, 202, 539–549. [Google Scholar] [CrossRef]
  5. Zhang, Y.; Zhang, Y.; Wang, F.; Wang, M.; Liu, H.; Chen, X.; Cao, P.; Ma, X.; Teng, W.; Zhang, X.; et al. The Mutational Spectrum of FLT3 Gene in Acute Lymphoblastic Leukemia Is Different from Acute Myeloid Leukemia. Cancer Gene Ther. 2019, 27, 81–88. [Google Scholar] [CrossRef]
  6. Molina Garay, C.; Carrillo Sánchez, K.; Flores Lagunes, L.L.; Jiménez Olivares, M.; Muñoz Rivas, A.; Villegas Torres, B.E.; Flores Aguilar, H.; Núñez Enríquez, J.C.; Jiménez Hernández, E.; Bekker Méndez, V.C.; et al. Profiling FLT3 Mutations in Mexican Acute Myeloid Leukemia Pediatric Patients: Impact on Overall Survival. Front. Pediatr. 2020, 8, 586. [Google Scholar] [CrossRef] [PubMed]
  7. Staffas, A.; Kanduri, M.; Hovland, R.; Rosenquist, R.; Ommen, H.B.; Abrahamsson, J.; Forestier, E.; Jahnukainen, K.; Jónsson, Ó.G.; Zeller, B. Presence of FLT3-ITD and High BAALC Expression Are Independent Prognostic Markers in Childhood Acute Myeloid Leukemia. Blood 2011, 118, 5905–5913. [Google Scholar] [CrossRef]
  8. Meshinchi, S.; Woods, W.G.; Stirewalt, D.L.; Sweetser, D.A.; Buckley, J.D.; Tjoa, T.K.; Bernstein, I.D.; Radich, J.P. Prevalence and Prognostic Significance of Flt3 Internal Tandem Duplication in Pediatric Acute Myeloid Leukemia. Blood 2001, 97, 89–94. [Google Scholar] [CrossRef]
  9. Qiu, K.; Liao, X.; Liu, Y.; Huang, K.; Li, Y.; Fang, J.; Zhou, D. Poor Outcome of Pediatric Patients with Acute Myeloid Leukemia Harboring High FLT3/ITD Allelic Ratios. Nat. Commun. 2022, 13, 3679. [Google Scholar] [CrossRef]
  10. Mead, A.J.; Linch, D.C.; Hills, R.K.; Wheatley, K.; Burnett, A.K.; Gale, R.E. FLT3 Tyrosine Kinase Domain Mutations Are Biologically Distinct from and Have a Significantly More Favorable Prognosis than FLT3 Internal Tandem Duplications in Patients with Acute Myeloid Leukemia. Blood 2007, 110, 1262–1270. [Google Scholar] [CrossRef]
  11. Alkhayat, N.; Elborai, Y.; Al Sharif, O.; Al Shahrani, M.; Alsuhaibani, O.; Awad, M.; Elghezal, H.; ben-abdallah Bouhajar, I.; Alfaraj, M.; Al Mussaed, E.; et al. Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia. Clin. Med. Insights Oncol. 2017, 11, 117955491772171. [Google Scholar] [CrossRef]
  12. Jerchel, I.S.; Hoogkamer, A.Q.; Ariës, I.M.; Steeghs, E.M.P.; Boer, J.M.; Besselink, N.J.M.; Boeree, A.; van de Ven, C.; de Groot-Kruseman, H.A.; de Haas, V.; et al. RAS Pathway Mutations as a Predictive Biomarker for Treatment Adaptation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Leukemia 2017, 32, 931–940. [Google Scholar] [CrossRef] [PubMed]
  13. Armstrong, S.A.; Mabon, M.E.; Silverman, L.B.; Li, A.; Gribben, J.G.; Fox, E.A.; Sallan, S.E.; Korsmeyer, S.J. FLT3 Mutations in Childhood Acute Lymphoblastic Leukemia. Blood 2004, 103, 3544–3546. [Google Scholar] [CrossRef] [PubMed]
  14. Kang, H.; Wilson, C.S.; Harvey, R.C.; Chen, I.-M.; Murphy, M.H.; Atlas, S.R.; Bedrick, E.J.; Devidas, M.; Carroll, A.J.; Robinson, B.W.; et al. Gene Expression Profiles Predictive of Outcome and Age in Infant Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. Blood 2012, 119, 1872–1881. [Google Scholar] [CrossRef] [PubMed]
  15. Chillón, M.C.; Gómez-Casares, M.T.; López-Jorge, C.E.; Rodriguez-Medina, C.; Molines, A.; Sarasquete, M.E.; Alcoceba, M.; Miguel, J.D.G.-S.; Bueno, C.; Montes, R.; et al. Prognostic Significance of FLT3 Mutational Status and Expression Levels in MLL-AF4+ and MLL-Germline Acute Lymphoblastic Leukemia. Leukemia 2012, 26, 2360–2366. [Google Scholar] [CrossRef]
  16. Taketani, T. FLT3 Mutations in the Activation Loop of Tyrosine Kinase Domain Are Frequently Found in Infant ALL with MLL Rearrangements and Pediatric ALL with Hyperdiploidy. Blood 2003, 103, 1085–1088. [Google Scholar] [CrossRef]
  17. Elyamany, G.; Awad, M.; Alsuhaibani, O.; Fadalla, K.; Al Sharif, O.; Al Shahrani, M.; Alabbas, F.; Al-Abulaaly, A. Flt3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance. Mediterr. J. Hematol. Infect. Dis. 2014, 6, e2014038. [Google Scholar] [CrossRef]
  18. Fedders, H.; Alsadeq, A.; Schmäh, J.; Vogiatzi, F.; Zimmermann, M.; Möricke, A.; Lenk, L.; Stadt, U.Z.; Horstmann, M.A.; Pieters, R.; et al. The Role of Constitutive Activation of FMS-Related Tyrosine Kinase-3 and NRas/KRas Mutational Status in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia. Haematologica 2017, 102, e438–e442. [Google Scholar] [CrossRef]
  19. Stam, R.W.; Schneider, P.; de Lorenzo, P.; Valsecchi, M.G.; den Boer, M.L.; Pieters, R. Prognostic Significance of High-Level FLT3 Expression in MLL-Rearranged Infant Acute Lymphoblastic Leukemia. Blood 2007, 110, 2774–2775. [Google Scholar] [CrossRef]
  20. Shen, H.; Laird, P.W. Interplay between the Cancer Genome and Epigenome. Cell 2013, 153, 38–55. [Google Scholar] [CrossRef]
  21. Pollard, J.A.; Alonzo, T.A.; Gerbing, R.; Brown, P.; Fox, E.; Choi, J.; Fisher, B.; Hirsch, B.; Kahwash, S.; Getz, K.; et al. Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children’s Oncology Group Protocol AAML1031. JCO 2022, 40, 2023–2035. [Google Scholar] [CrossRef] [PubMed]
  22. Zhang, J.; Zhang, Y.; Zhang, M.; Liu, C.; Liu, X.; Yin, J.; Wu, P.; Chen, X.; Yang, W.; Zhang, L.; et al. FLT3 Pathway Is a Potential Therapeutic Target for PRC2-Mutated T-Cell Acute Lymphoblastic Leukemia. Blood 2018, 132, 2520–2524. [Google Scholar] [CrossRef] [PubMed]
  23. Erba, H.P.; Montesinos, P.; Kim, H.-J.; Patkowska, E.; Vrhovac, R.; Žák, P.; Wang, P.-N.; Mitov, T.; Hanyok, J.; Kamel, Y.M.; et al. Quizartinib plus Chemotherapy in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2023, 401, 1571–1583. [Google Scholar] [CrossRef]
  24. Brown, P.A.; Kairalla, J.A.; Hilden, J.M.; Dreyer, Z.E.; Carroll, A.J.; Heerema, N.A.; Wang, C.; Devidas, M.; Gore, L.; Salzer, W.L.; et al. FLT3 Inhibitor Lestaurtinib plus Chemotherapy for Newly Diagnosed KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia: Children’s Oncology Group Trial AALL0631. Leukemia 2021, 35, 1279–1290. [Google Scholar] [CrossRef]
  25. Ley, T.J.; Mardis, E.R.; Ding, L.; Fulton, B.; McLellan, M.D.; Chen, K.; Dooling, D.; Dunford-Shore, B.H.; McGrath, S.; Hickenbotham, M.; et al. DNA Sequencing of a Cytogenetically Normal Acute Myeloid Leukaemia Genome. Nature 2008, 456, 66–72. [Google Scholar] [CrossRef] [PubMed]
  26. Tran, T.H.; Hunger, S.P. The Genomic Landscape of Pediatric Acute Lymphoblastic Leukemia and Precision Medicine Opportunities. Semin. Cancer Biol. 2020, 84, 144–152. [Google Scholar] [CrossRef] [PubMed]
  27. Shen, D.; Liu, L.; Xu, X.; Song, H.; Zhang, J.; Xu, W.; Zhao, F.; Liang, J.; Liao, C.; Wang, Y.; et al. Spectrum and Clinical Features of Gene Mutations in Chinese Pediatric Acute Lymphoblastic Leukemia. BMC Pediatr. 2023, 23, 62. [Google Scholar] [CrossRef]
  28. Bertrums, E.J.M.; Smith, J.L.; Harmon, L.; Ries, R.E.; Wang, Y.-C.J.; Alonzo, T.A.; Menssen, A.J.; Chisholm, K.M.; Leonti, A.R.; Tarlock, K.; et al. Comprehensive Molecular and Clinical Characterization of NUP98 Fusions in Pediatric Acute Myeloid Leukemia. Haematologica 2023, 108, 2044–2058. [Google Scholar] [CrossRef]
  29. Thanasopoulou, A.; Tzankov, A.; Schwaller, J. Potent Co-Operation between the NUP98-NSD1 Fusion and the FLT3-ITD Mutation in Acute Myeloid Leukemia Induction. Haematologica 2014, 99, 1465–1471. [Google Scholar] [CrossRef]
  30. Chauhan, P.S.; Ihsan, R.; Singh, L.C.; Gupta, D.K.; Mittal, V.; Kapur, S. Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features. Dis. Markers 2013, 35, 581–588. [Google Scholar] [CrossRef]
  31. Kiyoi, H.; Ohno, R.; Ueda, R.; Saito, H.; Naoe, T. Mechanism of Constitutive Activation of FLT3 with Internal Tandem Duplication in the Juxtamembrane Domain. Oncogene 2002, 21, 2555–2563. [Google Scholar] [CrossRef] [PubMed]
  32. Fröhling, S.; Scholl, C.; Levine, R.L.; Loriaux, M.; Boggon, T.J.; Bernard, O.A.; Berger, R.; Döhner, H.; Döhner, K.; Ebert, B.L.; et al. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Cancer Cell 2007, 12, 501–513. [Google Scholar] [CrossRef] [PubMed]
  33. Spiekermann, K.; Bagrintseva, K.; Schwab, R.; Schmieja, K.; Hiddemann, W. Overexpression and Constitutive Activation of FLT3 Induces STAT5 Activation in Primary Acute Myeloid Leukemia Blast Cells. Clin. Cancer Res. 2003, 9, 2140–2150. [Google Scholar] [PubMed]
  34. Reindl, C.; Bagrintseva, K.; Vempati, S.; Schnittger, S.; Ellwart, J.W.; Wenig, K.; Hopfner, K.-P.; Hiddemann, W.; Spiekermann, K. Point Mutations in the Juxtamembrane Domain of FLT3 Define a New Class of Activating Mutations in AML. Blood 2006, 107, 3700–3707. [Google Scholar] [CrossRef]
  35. Chatain, N.; Perera, R.C.; Rossetti, G.; Rossa, J.; Carloni, P.; Schemionek, M.; Haferlach, T.; Brümmendorf, T.H.; Schnittger, S.; Koschmieder, S. Rare FLT3 Deletion Mutants May Provide Additional Treatment Options to Patients with AML: An Approach to Individualized Medicine. Leukemia 2015, 29, 2434–2438. [Google Scholar] [CrossRef] [PubMed]
  36. Kazi, J.U.; Chougule, R.A.; Li, T.; Su, X.; Moharram, S.A.; Rupar, K.; Marhäll, A.; Gazi, M.; Sun, J.; Zhao, H.; et al. Tyrosine 842 in the Activation Loop Is Required for Full Transformation by the Oncogenic Mutant FLT3-ITD. Cell. Mol. Life Sci. 2017, 74, 2679–2688. [Google Scholar] [CrossRef] [PubMed]
  37. Rocnik, J.L.; Okabe, R.; Yu, J.-C.; Lee, B.H.; Giese, N.; Schenkein, D.P.; Gilliland, D.G. Roles of Tyrosine 589 and 591 in STAT5 Activation and Transformation Mediated by FLT3-ITD. Blood 2006, 108, 1339–1345. [Google Scholar] [CrossRef]
  38. Moorman, A.V.; Ensor, H.M.; Richards, S.M.; Chilton, L.; Schwab, C.; Kinsey, S.E.; Vora, A.; Mitchell, C.D.; Harrison, C.J. Prognostic Effect of Chromosomal Abnormalities in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia: Results from the UK Medical Research Council ALL97/99 Randomised Trial. Lancet. Oncol. 2010, 11, 429–438. [Google Scholar] [CrossRef]
  39. Sutcliffe, M.J.; Shuster, J.J.; Sather, H.N.; Camitta, B.M.; Pullen, J.; Schultz, K.R.; Borowitz, M.J.; Gaynon, P.S.; Carroll, A.J.; Heerema, N.A. High Concordance from Independent Studies by the Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Associating Favorable Prognosis with Combined Trisomies 4, 10, and 17 in Children with NCI Standard-Risk B-Precursor Acute Lymphoblastic Leukemia: A Children’s Oncology Group (COG) Initiative. Leukemia 2005, 19, 734–740. [Google Scholar] [CrossRef]
  40. Heerema, N.A.; Sather, H.N.; Sensel, M.G.; Zhang, T.; Hutchinson, R.J.; Nachman, J.B.; Lange, B.J.; Steinherz, P.G.; Bostrom, B.C.; Reaman, G.H.; et al. Prognostic Impact of Trisomies of Chromosomes 10, 17, and 5 among Children with Acute Lymphoblastic Leukemia and High Hyperdiploidy (>50 Chromosomes). JCO 2000, 18, 1876–1887. [Google Scholar] [CrossRef]
  41. Li, J.; Gao, J.; Liu, A.; Liu, W.; Xiong, H.; Liang, C.; Fang, Y.; Dai, Y.; Shao, J.; Yu, H.; et al. Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study. JCO 2023, 41, 4881–4892. [Google Scholar] [CrossRef] [PubMed]
  42. Schechter, T.; Gassas, A.; Chen, H.; Pollard, J.; Meshinchi, S.; Zaidman, I.; Hitzler, J.; Abdelhaleem, M.; Ho, R.; Domm, J.; et al. The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication–Positive Acute Myelogenous Leukemia. Biol. Blood. Marrow. Transplant. 2015, 21, 172–175. [Google Scholar] [CrossRef] [PubMed]
  43. Madero-Marroquin, R.; DuVall, A.S.; Saygin, C.; Wang, P.; Gurbuxani, S.; Larson, R.A.; Stock, W.; Patel, A.A. Durable Responses in Acute Lymphoblastic Leukaemia with the Use of FLT3 and IDH Inhibitors. Br. J. Haematol. 2023, 204, 1238–1242. [Google Scholar] [CrossRef]
  44. Janssen, M.; Schmidt, C.; Bruch, P.-M.; Blank, M.F.; Rohde, C.; Waclawiczek, A.; Heid, D.; Renders, S.; Göllner, S.; Vierbaum, L.; et al. Venetoclax Synergizes with Gilteritinib in FLT3 Wildtype High-Risk Acute Myeloid Leukemia by Suppressing MCL-1. Blood 2022, 140, 2594–2610. [Google Scholar] [CrossRef] [PubMed]
  45. Shao, R.; Zhang, Y.; He, J.; Huang, F.; Fan, Z.; Yang, K.; Xu, Y.; Xu, N.; Luo, Y.; Deng, L.; et al. Impact of Genetic Patterns on Sorafenib Efficacy in Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center, Cohort Study. Sig. Transduct. Target. Ther. 2023, 8, 348. [Google Scholar] [CrossRef]
  46. Jahn, N.; Jahn, E.; Saadati, M.; Bullinger, L.; Larson, R.A.; Ottone, T.; Amadori, S.; Prior, T.W.; Brandwein, J.M.; Appelbaum, F.R.; et al. Genomic Landscape of Patients with FLT3-Mutated Acute Myeloid Leukemia (AML) Treated within the CALGB 10603/RATIFY Trial. Leukemia 2022, 36, 2218–2227. [Google Scholar] [CrossRef]
  47. Smith, C.C.; Levis, M.J.; Perl, A.E.; Hill, J.E.; Rosales, M.; Bahceci, E. Molecular Profile of FLT3-Mutated Relapsed/Refractory Patients with AML in the Phase 3 ADMIRAL Study of Gilteritinib. Blood Adv. 2022, 6, 2144–2155. [Google Scholar] [CrossRef]
Ijms 25 09581 g001
Figure 1. The spectrum of FLT3 mutations in ALL (A) and in AML (B). Proportion of each mutation type in ALL (C) and in AML (D). Comparison of the proportions of each mutation type between ALL and AML (E). Comparison of the inserted base counts between ALL and AML (F). ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia. JMD, juxtamembrane domain; TMD, trans-membrane domain; TKD1, tyrosine kinase domain 1; TKD2, tyrosine kinase domain 2; KI, Kinase insert. In Figures (A,B), the colors orange, green, and black indicate non-canonical point mutations (NCPM), canonical tyrosine kinase domain (TKD) mutations, and internal tandem duplications (ITD), respectively. In Figure (A), gray and blue represent insertion/deletion (Indel) and insertion (INS), respectively, while in Figure (B), gray denotes deletion or deletion/insertion. The numbers in parentheses represent the number of patients with the mutation. ITD mutations in three AML patients were identified through transcriptome sequencing, but the specific loci are unknown and therefore are not shown in the Figure (B). *** p < 0.001. ** p < 0.01.
Figure 1. The spectrum of FLT3 mutations in ALL (A) and in AML (B). Proportion of each mutation type in ALL (C) and in AML (D). Comparison of the proportions of each mutation type between ALL and AML (E). Comparison of the inserted base counts between ALL and AML (F). ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia. JMD, juxtamembrane domain; TMD, trans-membrane domain; TKD1, tyrosine kinase domain 1; TKD2, tyrosine kinase domain 2; KI, Kinase insert. In Figures (A,B), the colors orange, green, and black indicate non-canonical point mutations (NCPM), canonical tyrosine kinase domain (TKD) mutations, and internal tandem duplications (ITD), respectively. In Figure (A), gray and blue represent insertion/deletion (Indel) and insertion (INS), respectively, while in Figure (B), gray denotes deletion or deletion/insertion. The numbers in parentheses represent the number of patients with the mutation. ITD mutations in three AML patients were identified through transcriptome sequencing, but the specific loci are unknown and therefore are not shown in the Figure (B). *** p < 0.001. ** p < 0.01.
Ijms 25 09581 g001
Ijms 25 09581 g002
Figure 2. Co-mutation landscape of FLT3 mutations in ALL (A) and in AML (B). Proportional distribution of co-mutations in ALL with FLT3 mutations (C) and in AML with FLT3 mutations (D). In Figures (A,B), the intensity of the color indicates the mutation frequency, with darker colors indicating a higher mutation frequency and lighter colors indicating a lower mutation frequency. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.
Figure 2. Co-mutation landscape of FLT3 mutations in ALL (A) and in AML (B). Proportional distribution of co-mutations in ALL with FLT3 mutations (C) and in AML with FLT3 mutations (D). In Figures (A,B), the intensity of the color indicates the mutation frequency, with darker colors indicating a higher mutation frequency and lighter colors indicating a lower mutation frequency. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.
Ijms 25 09581 g002
Ijms 25 09581 g003
Figure 3. Schematic diagram of the FLT3 pathways. This figure was created using Figdraw (https://www.figdraw.com/#/, Access Date: 1 September 2024).
Figure 3. Schematic diagram of the FLT3 pathways. This figure was created using Figdraw (https://www.figdraw.com/#/, Access Date: 1 September 2024).
Ijms 25 09581 g003
Table 1. Expression levels of FLT3 and associated pathway genes in ALL.
Table 1. Expression levels of FLT3 and associated pathway genes in ALL.
The Expression Level of Genes (FPKM)Total
(N = 206)		FLT3
Wild-Type
(N = 176)		FLT3
Mutant Group
(N = 30)		p
FLT3
(median [IQR])		31.34 [10.69, 80.33]23.11 [9.16, 59.14]108.02 [85.11, 142.06]<0.001
KRAS
(median [IQR])		22.18 [16.46, 30.70]22.05 [16.50, 29.30]25.03 [16.51, 34.23]0.476
HRAS
(median [IQR])		2.72 [2.05, 3.67]2.77 [2.08, 3.88]2.35 [1.57, 3.16]0.044
NRAS
(median [IQR])		33.62 [27.64, 40.39]33.46 [28.03, 40.29]35.90 [23.78, 42.71]0.865
PIK3CA
(median [IQR])		19.99 [15.59, 26.74]20.08 [15.73, 27.08]18.62 [15.03, 25.17]0.355
PIK3CB
(median [IQR])		5.76 [4.50, 7.15]5.74 [4.49, 7.16]5.83 [4.53, 7.04]0.786
PIK3CD
(median [IQR])		29.48 [20.69, 37.98]29.63 [21.19, 38.09]28.03 [18.95, 34.27]0.409
PIK3R3
(median [IQR])		1.89 [0.90, 3.49]2.02 [1.03, 3.84]1.33 [0.69, 1.77]0.002
AKT1
(median [IQR])		7.22 [6.04, 9.22]7.40 [6.10, 9.23]7.09 [5.56, 8.63]0.527
AKT2
(median [IQR])		9.83 [8.21, 11.75]10.18 [8.33, 11.79]8.53 [7.36, 10.89]0.058
AKT3
(median [IQR])		7.01 [2.77, 12.78]6.91 [2.85, 12.67]8.50 [2.71, 15.05]0.510
MTOR
(median [IQR])		9.90 [8.38, 11.71]9.98 [8.53, 11.76]9.66 [7.94, 10.84]0.267
CHUK
(median [IQR])		8.83 [7.23, 10.21]8.78 [7.22, 10.19]9.35 [8.38, 10.58]0.256
IKBKB
(median [IQR])		7.83 [6.60, 9.50]7.87 [6.64, 9.61]7.66 [6.39, 8.65]0.442
IKBKG
(median [IQR])		0.65 [0.50, 0.97]0.64 [0.50, 0.90]0.79 [0.51, 1.19]0.105
BAD
(median [IQR])		4.20 [3.04, 5.28]4.28 [3.11, 5.34]3.39 [2.25, 4.52]0.018
BRAF
(median [IQR])		15.13 [12.18, 18.94]15.15 [12.25, 18.98]13.68 [11.77, 18.74]0.571
RAF1
(median [IQR])		19.67 [16.29, 24.23]20.09 [16.39, 24.41]18.88 [14.94, 21.54]0.108
MAP2K1
(median [IQR])		11.16 [8.73, 14.23]11.08 [8.70, 13.32]11.90 [8.77, 16.70]0.323
MAP2K2
(median [IQR])		8.00 [6.54, 9.93]8.06 [6.88, 10.10]6.84 [4.03, 9.53]0.017
MAPK1
(median [IQR])		15.53 [13.36, 18.54]15.53 [13.42, 18.67]15.54 [13.16, 17.06]0.378
MAPK3
(median [IQR])		5.93 [4.88, 7.14]6.01 [5.01, 7.16]5.21 [3.92, 6.62]0.028
STAT3
(median [IQR])		13.76 [11.41, 19.61]13.76 [11.21, 19.13]14.15 [12.30, 20.44]0.495
STAT5A
(median [IQR])		14.12 [10.23, 19.31]14.58 [11.02, 19.61]12.31 [9.28, 15.57]0.029
STAT5B
(median [IQR])		16.90 [12.38, 21.67]17.59 [12.63, 22.01]14.92 [11.93, 18.83]0.069
Table 2. Expression levels of FLT3 and associated pathway genes in AML.
Table 2. Expression levels of FLT3 and associated pathway genes in AML.
The Expression Level of Genes (FPKM)Total
(N = 57)		FLT3
Wild-Type
(N = 38)		FLT3
Mutant Group
(N = 19)		p
FLT3
(median [IQR])		44.22 [26.32, 68.30]34.56 [20.98, 48.28]74.77 [54.31, 109.46]<0.001
KRAS
(median [IQR])		16.35 [13.13, 19.84]16.53 [13.46, 19.49]15.84 [12.70, 22.22]0.852
HRAS
(median [IQR])		2.96 [2.43, 3.89]2.77 [2.11, 3.77]3.17 [2.82, 3.91]0.123
NRAS
(median [IQR])		29.83 [24.84, 33.57]29.86 [25.28, 33.55]28.48 [23.02, 33.50]0.813
PIK3CA
(median [IQR])		10.25 [8.22, 12.43]10.46 [9.22, 13.13]9.06 [7.32, 11.24]0.09
PIK3CB
(median [IQR])		18.85 [14.46, 23.19]17.60 [13.28, 19.85]23.05 [18.81, 25.80]0.006
PIK3CD
(median [IQR])		18.70 [15.47, 24.77]18.50 [15.39, 24.73]19.53 [16.52, 25.39]0.813
PIK3R3
(median [IQR])		0.26 [0.18, 0.57]0.26 [0.18, 0.66]0.26 [0.16, 0.44]0.542
AKT1
(median [IQR])		8.32 [6.19, 10.41]7.40 [5.55, 8.88]9.66 [8.38, 11.61]0.003
AKT2
(median [IQR])		7.31 [5.61, 8.81]7.32 [5.57, 8.72]7.28 [6.35, 8.82]0.531
AKT3
(median [IQR])		1.66 [1.00, 4.42]1.52 [1.01, 3.34]2.50 [1.00, 5.00]0.379
MTOR
(median [IQR])		8.02 [7.21, 9.56]7.70 [6.79, 8.65]9.33 [7.75, 11.35]0.006
CHUK
(median [IQR])		7.63 [6.33, 9.19]7.62 [6.29, 8.80]7.82 [6.36, 9.82]0.542
IKBKB
(median [IQR])		7.96 [6.63, 9.41]7.59 [6.39, 9.54]8.55 [7.81, 9.36]0.128
IKBKG
(median [IQR])		0.72 [0.56, 0.88]0.71 [0.56, 0.87]0.76 [0.61, 0.91]0.488
BAD
(median [IQR])		3.47 [2.58, 4.20]3.12 [2.44, 4.05]3.76 [2.90, 4.61]0.108
BRAF
(median [IQR])		12.03 [10.37, 14.27]11.37 [9.61, 13.19]13.38 [11.63, 15.12]0.015
RAF1
(median [IQR])		18.03 [15.47, 20.86]17.99 [15.39, 20.16]18.44 [17.02, 21.18]0.623
MAP2K1
(median [IQR])		10.33 [7.56, 13.11]11.78 [7.00, 14.80]9.87 [8.22, 11.14]0.335
MAP2K2
(median [IQR])		9.76 [7.95, 11.72]9.30 [7.55, 11.59]10.04 [9.58, 11.68]0.123
MAPK1
(median [IQR])		13.25 [11.09, 16.73]12.72 [11.02, 14.92]14.84 [13.07, 17.90]0.029
MAPK3
(median [IQR])		6.65 [5.51, 7.69]6.95 [5.50, 7.99]6.19 [5.81, 7.25]0.416
STAT3
(median [IQR])		26.38 [22.24, 30.81]26.59 [22.31, 30.70]25.97 [22.98, 30.17]0.879
STAT5A
(median [IQR])		28.60 [22.79, 34.60]29.87 [21.83, 35.70]26.04 [23.79, 30.46]0.509
STAT5B
(median [IQR])		20.34 [17.39, 23.76]20.43 [17.92, 23.75]20.34 [17.29, 23.88]0.787
Abbreviations: AML, acute myeloid leukemia; IQR, interquartile range. Non-parametric test is used for statistical analysis.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhao, L.; Chen, H.; Lan, F.; Hao, J.; Zhang, W.; Li, Y.; Yin, Y.; Huang, M.; Wu, X. Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy. Int. J. Mol. Sci. 2024, 25, 9581. https://doi.org/10.3390/ijms25179581

AMA Style

Zhao L, Chen H, Lan F, Hao J, Zhang W, Li Y, Yin Y, Huang M, Wu X. Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy. International Journal of Molecular Sciences. 2024; 25(17):9581. https://doi.org/10.3390/ijms25179581

Chicago/Turabian Style

Zhao, Lizhen, Hongbo Chen, Fengli Lan, Jinjin Hao, Wenzhi Zhang, Ying Li, Yuhong Yin, Minchun Huang, and Xiaoyan Wu. 2024. "Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy" International Journal of Molecular Sciences 25, no. 17: 9581. https://doi.org/10.3390/ijms25179581

APA Style

Zhao, L., Chen, H., Lan, F., Hao, J., Zhang, W., Li, Y., Yin, Y., Huang, M., & Wu, X. (2024). Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy. International Journal of Molecular Sciences, 25(17), 9581. https://doi.org/10.3390/ijms25179581

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop